Genmab — Juli 2019
-
2 af de 4 spm Rajkumar stiller i tweetet, som MS linker til, skal nok blive diskuteret. Nemlig nr. 2 og 3: Om det nu også er alle, der behøver 4-stof-kombien, eller kun en del. Og kan de så fald identificeres. Og om man kan opnå samme effekt ved at undlade at give alle 4-kombien og så vente med dara til 1. relaps.
-
Anti-GPRC5D/CD3 bispecific T cell-redirecting antibody for the treatment of multiple myeloma https://www.ncbi.nlm.nih.gov/pubmed/31270154
-
(it would be nice if anyone could check if the whole article can be found via
https://sci-hub.tw/ ?) -
God morgen.
-
God morgen
-
-
DnB Markets
- Genmab (Buy, TP: DKK1540.00) - On course to reach the guidance
Genmab is only due to release its Q2 results at 17:00 CET on 14 August (we see focus being on progress in the pipeline and costs), while Johnson & Johnson is scheduled to report Darzalex sales almost a month earlier, on 16 July (we forecast global sales of USD696m, driven a strong performance in the US). We expect the full-year guidance for revenues of DKK4.6bn and EBIT of DKK2.0bn to be maintained, and reiterate our
- Genmab (Buy, TP: DKK1540.00) - On course to reach the guidance
-
Excellent. Thank you E L. About time they started adjusting in the other direction.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind